This article was originally distributed via PRWeb. PRWeb, WorldNow and this Site make no warranties or representations in connection therewith.
SOURCE: Voices Against Brain Cancer
Following an article detailing one brain tumor clinic’s determination to find new treatments for brain cancer, Voices Against Brain Cancer releases statement
New York, NY (PRWEB) October 08, 2012
According to a recent article by [Hope Jensen of WRDW News 12, “Nearly 23,000 people will be diagnosed with brain cancer this year according to the National Cancer Institute. The average person diagnosed with a brain tumor will only live around 12-14 months, but at GHSU's Cancer Center they are working to change that.” Jensen goes on to state, “The center just received a new grant that is allowing them to partner with a drug development company in France to come up with new drug therapies. The company was in Augusta last week touring the facilities and will be opening up a branch at the cancer center to work with Dr. Rixe on the drug development.”
VABC representative Clay Darrohn states: “We commend the determination of GHSU’s Cancer Center in their determination to find new treatments for this devastating diagnosis. It is imperative that the world continue to research and explore new alternatives in order to help those diagnosed with and affected by brain cancer.”
VABC has a wide variety of initiatives in place for brain cancer research, awareness and support. The organization’s research grants fund cutting-edge research programs that will have a monumental impact on the diagnosis and treatment of brain cancer. VABC currently funds research at several esteemed institutions such as Brookhaven National Laboratory, Cleveland Clinic, Columbia, Cornell, Duke, Harvard, John Hopkins, Memorial Sloan-Kettering and Yale, to name a few.
VABC's mission is to find a cure for brain cancer by advancing scientific research, increasing awareness within the medical community and supporting patients, their families and caregivers afflicted with this devastating disease.
For press inquiries, please contact: 5W Public Relations.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb9983449.htm